Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access - Seite 2

About Sandoz
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.

Follow our blog at www.sandoz.com/makingaccesshappen.

References:

       [1]   European Medicines Agency. Hyrimoz. Key Facts. Available at: https://www.ema.europa.eu/medicines/human/EPAR/hyrimoz. Accessed October 2, 2018.

^**Humira (adalimumab) is marketed by AbbVie Deutschland GmbH & Co. KG in Europe and Humira is a registered trademark of AbbVie Biotechnology, Inc.

# # #

  
Novartis Media Relations
Central media line: [phone]
E-mail: [e-mail]

Eric Althoff Novartis Global Media Relations [phone] (direct) [phone] (mobile) [e-mail]
Chris Lewis Sandoz Global Communications [phone] (direct) [phone] (mobile) [e-mail]	Michelle Bauman Sandoz Global Communications ++1 609 720 6699 (direct) ++1 973 714 8043 (mobile) [e-mail]

Novartis Investor Relations
Central investor relations line: [phone]
E-mail: [e-mail]

Central		North America
Samir Shah	[phone]	Richard Pulik	[phone]
Pierre-Michel Bringer	[phone]	Cory Twining	[phone]
Thomas Hungerbuehler	[phone]
Isabella Zinck	[phone]